KYNBNasdaqPharmaceutical PreparationsFiscal year ends December 31
KYNTRA BIO, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$5.28+0.43 (+8.87%)
Close on Oct 19, 2026
- Market cap
- $21.37M
- P/E (TTM)
- 0.1
- Dividend yield
- –
KYNTRA BIO, INC. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other Revenue - Contract Manufacturing [Member] | $103.00K | $246.00K | $196.00K | $119.00K | $133.00K | $144.00K | $416.00K | $385.00K | $269.00K | $878.00K | $2.58M | $6.78M | – | -22.6% |
| Drug Product Revenue [Member] | -$1.58M | $3.49M | $1.08M | $957.00K | $1.22M | $2.60M | $2.72M | -$262.00K | $729.00K | $24.49M | $1.05M | $1.32M | – | -229.8% |
| License [Member] | – | – | – | – | – | – | $0 | $0 | $0 | $0 | $0 | $2.65M | – | – |
| Product [Member] | – | – | – | – | – | – | – | $46.21M | $49.64M | $30.54M | $23.51M | $29.39M | – | – |
By region
From the segment and revenue-disaggregation notes of Kyntra Bio's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.